PCSK9 and atherosclerosis: Similarly, a more extended FOURIER-OLE study with a median follow-up time of 5 years concluded that PCSK9 inhibitor use did not significantly increase the incidence of serious adverse events, including neurocognitive impairment or new-onset diabetes mellitus in patients with ASCVD (ODonoghue et al., 2022).